{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:38:39Z","timestamp":1788813519047,"version":"build-2803163510"},"reference-count":80,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin disorder that significantly affects patients\u2019 quality of life. Dupilumab, a monoclonal antibody targeting interleukin (IL)-4 receptor alpha (IL-4R\u03b1), has been the standard biologic therapy for moderate-to-severe AD. This review compares dupilumab with tralokinumab\u2014a promising alternative that selectively neutralizes IL-13\u2014by examining their distinct mechanisms, clinical efficacy, safety profiles, and practical considerations. While both biologics are highly effective, pivotal monotherapy trials indicate numerically higher efficacy rates for dupilumab. Regarding safety, while long-term data show comparable rates of serious adverse events, dupilumab is associated with a higher incidence of both conjunctivitis and injection-site reactions. Key practical differences include dupilumab\u2019s broader indications and approval for infants (\u22656 months), versus tralokinumab\u2019s flexible maintenance dosing and notable efficacy in head and neck AD. By highlighting these key distinctions, this review aims to support personalized treatment selection in AD. However, no direct head-to-head clinical trials have yet compared dupilumab and tralokinumab, and the available evidence is based on indirect comparisons from separate pivotal studies.<\/jats:p>","DOI":"10.3390\/jcm14144960","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T10:55:41Z","timestamp":1752490541000},"page":"4960","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative Efficacy and Safety of Tralokinumab and Dupilumab in Moderate-to-Severe Atopic Dermatitis: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Yoon-Seob","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Dermatology, Bucheon St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1361005","DOI":"10.3389\/fimmu.2024.1361005","article-title":"Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches","volume":"15","author":"Afshari","year":"2024","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: An expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Pareek, A., Kumari, L., Pareek, A., Chaudhary, S., Ratan, Y., Janmeda, P., Chuturgoon, S., and Chuturgoon, A. (2024). Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives. Cells, 13.","DOI":"10.3390\/cells13050425"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mesjasz, A., Ko\u0142kowski, K., Wollenberg, A., and Trzeciak, M. (2023). How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087557"},{"key":"ref_8","first-page":"495","article-title":"Neuro\u2013immuno\u2013endocrinology of the skin: How environment regulates body homeostasis","volume":"21","author":"Slominski","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"Chu","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: Part I\u2014Systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s13555-025-01357-7","article-title":"Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy","volume":"15","author":"Silverberg","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jaci.2003.09.033","article-title":"Atopic dermatitis and the atopic march","volume":"112","author":"Spergel","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5021\/ad.24.049","article-title":"2023 Consensus Korean Diagnostic Criteria for Atopic Dermatitis","volume":"37","author":"Lee","year":"2025","journal-title":"Ann. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.anai.2023.09.009","article-title":"Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives","volume":"132","author":"Stefanovic","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41467-023-41180-2","article-title":"European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation","volume":"14","author":"Kilanowski","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/ng.3424","article-title":"Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis","volume":"47","author":"Paternoster","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","article-title":"Significance of Skin Barrier Dysfunction in Atopic Dermatitis","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Grafanaki, K., Bania, A., Kaliatsi, E.G., Vryzaki, E., Vasilopoulos, Y., and Georgiou, S. (2023). The Imprint of Exposome on the Development of Atopic Dermatitis across the Lifespan: A Narrative Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062180"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell Mol. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100131","DOI":"10.1016\/j.xjidi.2022.100131","article-title":"Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis","volume":"2","author":"Beck","year":"2022","journal-title":"JID Innov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.immuni.2023.03.014","article-title":"The ins and outs of innate and adaptive type 2 immunity","volume":"56","author":"Molofsky","year":"2023","journal-title":"Immunity"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Fania, L., Moretta, G., Antonelli, F., Scala, E., Abeni, D., Albanesi, C., and Madonna, S. (2022). Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052684"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.anai.2023.11.020","article-title":"Diversity of atopic dermatitis and selection of immune targets","volume":"132","author":"Bar","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Maurelli, M., Calabrese, L., Peris, K., and Girolomoni, G. (2023). Overview of Atopic Dermatitis in Different Ethnic Groups. J. Clin. Med., 12.","DOI":"10.20944\/preprints202302.0458.v1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4168\/aair.2025.17.2.165","article-title":"Skin Microbiome Dynamics in Atopic Dermatitis: Understanding Host-Microbiome Interactions","volume":"17","author":"Kim","year":"2025","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.04.029","article-title":"Exploring the skin microbiome in atopic dermatitis pathogenesis and disease modification","volume":"154","author":"Rohayem","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4168\/aair.2018.10.4.354","article-title":"Microbiome in the Gut-Skin Axis in Atopic Dermatitis","volume":"10","author":"Lee","year":"2018","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kim, J.E., and Kim, H.S. (2019). Microbiome of the Skin and Gut in Atopic Dermatitis (AD): Understanding the Pathophysiology and Finding Novel Management Strategies. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040444"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"720393","DOI":"10.3389\/fimmu.2021.720393","article-title":"Gut Microbiota, Probiotics, and Their Interactions in Prevention and Treatment of Atopic Dermatitis: A Review","volume":"12","author":"Fang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1194254","DOI":"10.3389\/fcimb.2023.1194254","article-title":"Atopic dermatitis-derived Staphylococcus aureus strains: What makes them special in the interplay with the host","volume":"13","author":"Conte","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.alit.2021.11.001","article-title":"Skin microbiome of atopic dermatitis","volume":"71","author":"Koh","year":"2022","journal-title":"Allergol. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrmicro2537","article-title":"The skin microbiome","volume":"9","author":"Grice","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40413-017-0160-5","article-title":"The skin microbiome: Impact of modern environments on skin ecology, barrier integrity, and systemic immune programming","volume":"10","author":"Prescott","year":"2017","journal-title":"World Allergy Organ. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.jaci.2022.03.010","article-title":"Neuroimmune communication regulating pruritus in atopic dermatitis","volume":"149","author":"Steinhoff","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.alit.2022.04.003","article-title":"Peripheral itch sensitization in atopic dermatitis","volume":"71","author":"Tominaga","year":"2022","journal-title":"Allergol. Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1258823","DOI":"10.3389\/fnmol.2023.1258823","article-title":"Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli","volume":"16","author":"Mack","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1260345","DOI":"10.3389\/fnmol.2023.1260345","article-title":"Scratching increases epidermal neuronal branching and alters psychophysical testing responses in atopic dermatitis and brachioradial pruritus","volume":"16","author":"Renkhold","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1272230","DOI":"10.3389\/fnmol.2023.1272230","article-title":"Itch: From the skin to the brain\u2014Peripheral and central neural sensitization in chronic itch","volume":"16","author":"Mahmoud","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2022.06.012","article-title":"Modulation of IL-4\/IL-13 cytokine signaling in the context of allergic disease","volume":"150","author":"Shankar","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaci.2024.10.002","article-title":"A partial loss-of-function variant in STAT6 protects against type 2 asthma","volume":"155","author":"Kristjansdottir","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1165098","DOI":"10.3389\/fmed.2023.1165098","article-title":"The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis","volume":"10","author":"Napolitano","year":"2023","journal-title":"Front. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s13555-025-01352-y","article-title":"Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review","volume":"15","author":"Torres","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: A placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"Smith","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","article-title":"Dupilumab in Adults with Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study","volume":"160","author":"Beck","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.16928","article-title":"A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: Pharmacokinetics, safety and efficacy","volume":"35","author":"Paller","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40257-024-00859-y","article-title":"Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study","volume":"25","author":"Paller","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","article-title":"Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6\u201311 Years of Age with Severe Atopic Dermatitis","volume":"13","author":"Cork","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: A placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: Pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_67","unstructured":"(2025, July 09). Available online: https:\/\/www.businesswire.com\/news\/home\/20241025193860\/en\/LEO-Pharma-Presents-Final-Results-of-ECZTEND-Long-Term-Adbry-Trial-tralokinumab-ldrm-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis-AD-at-Fall-Clinical-2024."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"s375","DOI":"10.25251\/skin.8.supp.375","article-title":"Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials","volume":"8","author":"Reich","year":"2024","journal-title":"Ski. J. Cutan. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40257-025-00931-1","article-title":"Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years","volume":"26","author":"Chovatiya","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/bjd\/ljae439","article-title":"Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis","volume":"192","author":"Weidinger","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1419164","DOI":"10.3389\/fimmu.2024.1419164","article-title":"Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A prospective real-world cohort study in China","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","article-title":"Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells","volume":"15","author":"Bangert","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/bjd.21019","article-title":"Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: A multicentre, prospective cohort study","volume":"186","author":"Kozera","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: Results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s13555-025-01395-1","article-title":"Complete\/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry","volume":"15","author":"Bhatia","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Walig\u00f3ra-Dziwak, K., Da\u0144czak-Pazdrowska, A., and Jenerowicz, D. (2025). Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in Early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094230"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"s574","DOI":"10.25251\/skin.10.supp.574","article-title":"Real-world Effectiveness of Tralokinumab in Adults with Atopic Dermatitis: Interim Data on Improvements in Patients with Head and Neck Atopic Dermatitis after up to 9 Months of Treatment in the TRACE Study","volume":"9","author":"Armstrong","year":"2025","journal-title":"Ski. J. Cutan. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s13555-025-01341-1","article-title":"Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study","volume":"15","author":"Tolino","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2216815","DOI":"10.1080\/09546634.2023.2216815","article-title":"Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: A real-life 16-week experience","volume":"34","author":"Gargiulo","year":"2023","journal-title":"J. Dermatolog Treat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/14\/4960\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:09:17Z","timestamp":1760033357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/14\/4960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":80,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14144960"],"URL":"https:\/\/doi.org\/10.3390\/jcm14144960","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,13]]}}}